Clinical Article

https://doi.org/10.3340/jkns.2023.0176

Protein Requirement Changes According to the Treatment Application in Neurocritical Patients

Jungook Kim,1,* Youngbo Shim,2,* Yoon-Hee Choo,3 Hye Seon Kim,4 Young ran Kim,5 Eun Jin Ha6,7
Department of Traumatology,1 Gachon University Gil Medical Center, Incheon, Korea
Department of Critical Care Medicine,2 Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Department of Neurosurgery,3 Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Department of Neurosurgery,4 Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea
SMG-SNU Boramae Medical Center,5 Seoul, Korea
Department of Critical Care Medicine,6 Seoul National University Hospital, Seoul, Korea
Department of Neurosurgery,7 Seoul National University Hospital, Seoul, Korea

Running Title: Protein for Neurocritical Patients

• Received : August 25, 2023 • Revised : November 4, 2023 • Accepted : November 16, 2023

Address for correspondence : Eun Jin Ha
Department of Neurosurgery and Critical Care Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel : +82-2-2072-3639, Fax : +82-2-744-8459, E mail : 65932@snuh.org, ORCID : https://orcid.org/0000-0003-3278-0550

*Two authors have contributed equally as co-first authors.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2023 The Korean Neurosurgical Society
ABSTRACT

Objective: Exploring protein requirements for critically ill patients has become prominent. On the other hand, considering the significant impact of coma therapy and targeted temperature management (TTM) on the brain as well as systemic metabolisms, protein requirements may plausibly be changed by treatment application. However, there is currently no research on protein requirements following the application of these treatments. Therefore, the aim of this study is to elucidate changes in patients’ protein requirements during the application of TTM and coma therapy.

Methods: This study is a retrospective analysis of prospectively collected data from March 2019 to May 2022. Among the patients admitted to the intensive care unit, those receiving coma therapy and TTM were included. The patient’s treatment period was divided into two phases (Phase 1: application and maintenance of coma therapy and TTM; Phase 2: tapering and cessation of treatment). In assessing protein requirements, the Urine Urea Nitrogen (UUN) method was employed to estimate the nitrogen balance, offering insight into protein utilization within the body. The patient’s protein requirement for each phase was defined as the amount of protein required to achieve a nitrogen balance within ±5, based on the 24-hour collection of UUN. Changes in protein requirements between phases were analyzed.

Results: Out of 195 patients, 107 patients with a total of 214 UUN values were included. The mean protein requirement for the entire treatment period was 1.84 ± 0.62 g/kg/day, which is higher than the generally recommended protein supply of 1.2 g/kg/day. As the treatment was tapered, there was a statistically significant increase in the protein requirement from 1.49 ± 0.42 to 2.18 ± 0.60 in phase 2 (p < 0.001).

Conclusion: Our study revealed a total average protein requirement of 1.84 ± 0.62g during the treatment period, which falls within the upper range of the preexisting guidelines. Nevertheless, a notable deviation emerged when analyzing the treatment application period separately. Hence, it is recommended to incorporate considerations for the type and timing of treatment, extending beyond the current guideline, which solely accounts for the ‘severity by disease.’

Key Words: Neurocritical care · Protein supply · Nitrogen balance · Nutrition support · Urine urea
INTRODUCTION

Exploring protein requirements for critically ill patients has become prominent. Adequate protein intake can reduce mortality\(^{20}\) and prevent various complications such as organ failure\(^{21}\), sarcopenia\(^{24}\), immune compromise\(^{5}\), and failure of wound healing\(^{26}\), leading to post-intensive care syndrome\(^{14}\) and ultimately impacting functional outcomes. In this respect, current nutritional guidelines recommend adequate amounts of protein for critical patients, apart from appropriate calorie suggestions. The American Society for Parenteral and Enteral Nutrition (ASPEN) recommends a protein intake of between 1.2 and 2 grams per kilogram (g/kg) of body weight per day, based on the severity of the disease\(^{8}\).

However, the above guidelines have several limitations. Firstly, the suggested protein intake range (1.2–2.0 g/kg/day) is broad, which may lead to confusion in determining the exact protein requirements for critically ill patients. Secondly, apart from the severity of the disease itself, the patient's individual severity changes with each treatment phase, making it questionable to set a fixed protein intake. The third limitation is that the existing guidelines do not consider the specific factors crucial for neurocritical patients.

Measuring protein requirements in patients with brain injuries poses several challenges. One is the impact of the brain itself, which accounts for 20% of total energy expenditure and may be compromised\(^{12}\). Additionally, protein catabolism due to the systemic inflammatory response following brain damage must also be considered\(^{7}\). Yet, these tribulations do not stand alone. The implementation of coma therapy or targeted temperature management (TTM) introduces further complexities, as the therapy reduces the metabolic rate of the brain to prevent secondary neurological damage, thereby affecting the patient's basal metabolic rate\(^{1,22}\). Collectively, these factors impede the study of protein requirements in neurocritical patients. To date, studies on the protein requirements of neurocritical patients have primarily been limited to traumatic brain injury\(^{17}\), with a lack of research considering individual
severity or the treatment chronomically.

This study aims to identify changes in protein requirements during the process of neurocritical treatment, which includes coma therapy and TTM. We hypothesized that protein requirements would decrease during these treatments and increase during weaning.

MATERIALS AND METHODS

Study population

We retrospectively identified data collected prospectively from patients who were admitted to our intensive care unit (ICU) and underwent coma therapy, or TTM, for more than 72 hours from March 2019 to May 2022. Patients with oliguria or chronic kidney disease making urine collection challenging, as well as those lacking sufficient data for each treatment phase established in the study, were excluded. Patient consent was waived under IRB approval (2209-076-1358) for this retrospective study.

Baseline characteristics and clinical information

Baseline characteristics, including age, sex, initial body weight and height, and medical history (e.g., diabetes mellitus, hypertension, dyslipidemia, heart disease, stroke, and cancer), were evaluated. In addition, we obtained clinical information regarding the initial Glasgow Coma Scale (GCS), length of stay in the ICU, starting time and ending time of TTM, and coma therapy.

Treatment strategies

Application of coma therapy and TTM

When patients with a GCS score of less than 8 were admitted to the ICU, intracranial pressure (ICP) monitoring was implemented if there was evidence of ICP elevation within brain computed tomography (CT). If the ICP remained above 22 mmHg despite appropriate baseline management, such as head elevation to 30-45 degrees, maintaining normotension, normothermia, normocapnia, euvoledma, and
osmotic therapy, coma therapy using continuous infusions of thiopental or propofol was applied. Simultaneously, if no contraindications, such as coagulopathy, were present, TTM was utilized to lower the patient's body temperature to 35 degrees Celsius. In cases where refractory ICP elevation persisted, further lowering of the body temperature, down to 34 or even 33 degrees Celsius, was considered. The study was conducted exclusively on patients who had successfully undergone coma therapy and TTM without experiencing severe complications.

Tapering of treatment

After patients receiving coma therapy and TTM had their ICP well controlled on the monitors for a certain period (24-48 hours), a brain CT was performed to confirm the absence of additional threats to ICP elevation, such as delayed cerebral ischemia (DCI) or hemorrhage re-expansion. Subsequently, the tapering of treatment was initiated. Coma therapy involved gradually reducing the drug concentration by one hour, while TTM increased the temperature by 0.05 degrees Celsius per hour until reaching a target of 36 degrees Celsius. During the progressive tapering process, if there was no significant increase in ICP, coma therapy transitioned to light sedation using dexmedetomidine. For TTM, after reaching 36 degrees Celsius, normothermia was maintained for 24 hours, and if the ICP remained tolerable, the same method was used to raise the temperature to 37 degrees Celsius before discontinuation. The duration of the treatment application was approximately 7 to 10 days.

Protein requirement monitoring with urine urea nitrogen (UUN)

We analyzed protein requirements using UUN measurements from urine collected via a Foley catheter over a 24-hour period. During the treatment application and maintenance phases, one test was conducted, and an additional test was performed during the tapering phase after achieving the treatment goals. We divided the entire treatment period into two groups, namely phase 1 and phase 2, for comparison. Phase 1 was defined as the period from the initiation of coma therapy and TTM until just before tapering, while phase 2 was defined as the period from the start of tapering until the discontinuation of coma therapy and TTM. According to Bingham et al. 4, the patient's 'protein requirement' was defined as the
protein mass needed to achieve a nitrogen balance within ± 5. In this study, we adopted the same approach to calculate the patient's protein requirement. The formula used for the calculation is as follows: \( \text{Nitrogen balance (NB)} (\text{g/day}) = \frac{\text{Protein intake (g)}}{6.25} - (\text{UUN+4}) \)

**Statistical analysis**

We compared the protein requirement for each phase using the Wilcoxon rank-sum test and performed the Dunn's test for post hoc analyses. The same methods were used for subgroup analyses by diagnoses. All statistical analyses were performed using R software.

**RESULTS**

**Patient characteristics**

Data from 195 patients was collected between March 2019 and May 2022. Out of these, 88 patients who met the exclusion criteria were excluded, including three with renal impairment and 85 with insufficient UUN data for each phase. Ultimately, a total of 214 UUN data points from 107 patients were utilized for the analyses.

Among the patients, 44.9% were male (n = 48), and the mean age was 56.6 ± 17.8 years. Twenty-five patients (23.4%) had a history of diabetes mellitus (DM), 34 (31.8%) had hypertension, 11 (10.3%) had heart disease, and 15 (14.0%) had a history of stroke. Twelve patients (11.2%) had a history of cancer.

Regarding the specific diagnoses, 28 (26.7%) patients were diagnosed with subarachnoid hemorrhage (SAH), 27 (25.7%) with intracerebral hemorrhage (ICH), 22 (21.0%) with brain tumor, 18 (17.1%) with traumatic brain injury (TBI), 5 (4.8%) with ischemic stroke, and 3 (2.9%) with pure intraventricular hemorrhage. The median initial GCS score was 9 (range: 6-14), and the modified Rankin Scale (mRS) score was 4 (range: 3-5). The mean length of stay in the ICU was 19.5 ± 13.9 days (Table 1).

**Estimated protein requirement**
Out of the total 214 UUN data collected from 107 patients, the mean value of protein requirements, as measured by UUN throughout the entire period, was $1.84 \pm 0.62 \text{ g/kg/day}$. During phase 1, the protein requirement was $1.49 \pm 0.42 \text{ g/kg/day}$, while in phase 2, as the treatment was tapered, it increased to $2.18 \pm 0.60 \text{ g/kg/day}$. This increase demonstrates statistical significance ($P < 0.001$, Fig. 1).

In the subgroup analyses based on specific diagnoses, consistent findings were observed. For patients diagnosed with SAH, the protein requirement during phase 1 was $1.39 \pm 0.31 \text{ g/kg/day}$, which increased to $2.16 \pm 0.55 \text{ g/kg/day}$ during phase 2. Similarly, in patients with ICH, the protein requirement was $1.56 \pm 0.49 \text{ g/kg/day}$ in phase 1 and increased to $2.32 \pm 0.80 \text{ g/kg/day}$ in phase 2. Patients with brain tumors demonstrated a protein requirement of $1.62 \pm 0.54 \text{ g/kg/day}$ in phase 1, rising to $2.17 \pm 0.49 \text{ g/kg/day}$ in phase 2. Likewise, those with TBI exhibited a protein requirement of $1.42 \pm 0.27 \text{ g/kg/day}$ in phase 1 and $2.14 \pm 0.48 \text{ g/kg/day}$ in phase 2. In all subgroups, a significant increase was observed between phases, demonstrating the clinical relevance of these findings (Fig. 2).

**DISCUSSION**

**Importance of protein in critical patients**

Protein is the essential macronutrient for wound healing, immune function, and maintaining body mass in critically ill patients, and thus is more than just a source of calories\(^8\). Compher and colleagues showed that the odds of death decreased by 6.6% with each 10% increase in protein intake\(^8\). Furthermore, adequate protein intake was also found to help reduce the time to wean from the ventilator and shorten the length of stay in the ICU\(^16\). A lot of guidelines emphasize protein intake, recognizing its significance beyond providing calories. According to the 2016 ASPEN guidelines, critically ill patients require 1.2 to 2.0 g/kg of protein per day, with higher protein intake recommended for severe stress situations such as burns and multiple fractures\(^19\). Specifically, for TBI, the guideline suggests a protein intake as high as 1.5-2.5 g/kg/day, which aligns with our findings. The 2019 ESPEN guideline also recommends supplying at least 1.3 g/kg of protein daily to critically ill patients\(^25\).

In general, critically ill patients are likely to fall into a catalytic state in the acute phase, so the demand
for systemic and protein metabolism increases. However, some reports showed that patients receive only 25-60% of their protein requirements on average during intensive care, which was also associated with a poor prognosis. While neurocritical patients have more stress factors than other critical patients, it has been confirmed that they experience negative nitrogen balance and protein shortage problems.

Neurocritical treatments and metabolism

Since the brain is a high-nutrient-metabolic organ that uses 20% of total energy expenditure (TEE), changes in brain metabolism can also lead to changes in the patient's TEE. This is related not only to protein catabolism caused by the systemic inflammatory response along with brain damage but also to the intensity level of treatment applied. Neurocritical treatments, such as coma therapy, deep sedation, or TTM, lower the brain metabolism rate and decrease ICP. Previous studies have shown that the resting metabolic rate (RMR) is reduced by 25% when propofol sedation is applied. Body temperature is also a factor that affects energy consumption. It is known that the cerebral metabolic rate decreases by 5 to 7% and energy consumption by 10 to 13% with every drop of a degree Celsius in the body temperature. Coma therapy is also known to reduce systemic metabolism and body temperature. Nevertheless, limited research has been conducted regarding the impact of these therapies on protein metabolism. Through the ICP-guided treatment, we successfully maintained ICP and optimal cerebral perfusion pressure in most patients included in our study. Despite the adequate utilization of coma therapy and TTM, the protein requirements identified in our study (1.50 ± 0.44 g/kg/day) fell within the upper range of the preexisting guideline, as suggested by ASPEN. These requirements would have been higher if coma therapy or TTM were not applied. Consequently, if nutrition supply is planned based on the overall reduced calorie requirements, it becomes difficult to supply sufficient protein. Buckley et al. also highlighted that patients may be at risk of protein deficiency during propofol sedation.

Significant increase in protein requirement during treatment weaning
Considering the impact of protein on neurological patients, it is essential to probe protein requirements with regard to brain metabolism. In our study, a significant increase in protein requirements was observed between phases 1 and 2. Therefore, it would be more advisable to monitor protein requirements at each treatment phase than at regular intervals. By measuring protein requirements and supplying an adequate amount, we can minimize protein shortages. Furthermore, while the overall caloric demand diminishes due to the effects of interventions such as coma therapy and TTM, the protein requirement during phase 1 remains notably high (1.49 ± 0.42). Given this, it becomes necessary to contemplate how to incorporate these findings into the patient's nutritional plan. Of course, research on functional outcomes should precede this.

Limitations
First, as a retrospective study, it is crucial to acknowledge that this research is inherently constrained by some missing data. Second, conducting a comprehensive analysis of factors that might influence UUN, such as blood transfusions, vasopressor usage, and patients' digestive capacity, was challenging due to methodological complexities. Third, in the cases of relatively mild patients who did not undergo coma therapy and TTM in neurocritical care or non-neurocritical patients, we did not perform early and thorough UUN analysis, so there were no control groups to confirm the increased protein requirement and its changes. Fourth, we did not observe an association between protein supplementation using UUN and clinical outcomes. Nevertheless, this study lays the groundwork for future investigations that explore the potential benefits of tailoring protein supplementation based on individual patients' specific protein requirements to enhance their clinical outcomes.

CONCLUSION

In neurocritical patients, especially those undergoing treatments like coma therapy or TTM that influence metabolism, significant changes in protein requirements were observed. Considering these findings, it may be necessary to reevaluate the current protein supply guidelines that solely rely on the
'severity index of the disease'. Further assessment is warranted to determine the appropriateness and relevance of the existing protein guidelines considering these significant variations in protein needs.

AUTHORS’ DECLARATION

Conflicts of interest

No potential conflicts of interest relevant to this study exist.

Informed consent

This type of study does not require informed consent.

Author contributions

Conceptualization : EJH, YRK; Data curation : JOK, YBS, YHC, HSK; Formal analysis : YBS; Methodology : JOK; Visualization : YBS; Writing - original draft : JOK; Writing - review & editing : YBS, YRK, EJH

Data sharing

None

Preprint

None
ORCID

Jungook Kim https://orcid.org/0000-0002-6667-6447
Youngbo Shim https://orcid.org/0000-0002-3350-362X
Yoon-Hee Choo https://orcid.org/0000-0002-6077-6893
Hye Seon Kim https://orcid.org/0000-0002-0298-2402
Young ran Kim https://orcid.org/0009-0005-8263-7260
Eun Jin Ha https://orcid.org/0000-0003-3278-0550

References


<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>48 (44.9)</td>
</tr>
<tr>
<td>Female</td>
<td>59 (55.1)</td>
</tr>
<tr>
<td><strong>Age (year)</strong></td>
<td>56.6 ± 17.8</td>
</tr>
<tr>
<td><strong>Initial body weight (Kg)</strong></td>
<td>62.8 ± 15.2</td>
</tr>
<tr>
<td><strong>Initial height (cm)</strong></td>
<td>163.0 ± 9.9</td>
</tr>
<tr>
<td><strong>Initial BMI (kg/m²)</strong></td>
<td>23.4 ± 4.2</td>
</tr>
<tr>
<td><strong>Underlying disease</strong></td>
<td></td>
</tr>
<tr>
<td>DM</td>
<td>25 (23.4)</td>
</tr>
<tr>
<td>HTN</td>
<td>34 (31.8)</td>
</tr>
<tr>
<td>DI</td>
<td>23 (21.5)</td>
</tr>
<tr>
<td>Heart disease</td>
<td>11 (10.3)</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>15 (14.0)</td>
</tr>
<tr>
<td>Cancer</td>
<td>12 (11.2)</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>SAH</td>
<td>28 (26.7)</td>
</tr>
<tr>
<td>ICH</td>
<td>27 (25.7)</td>
</tr>
<tr>
<td>TBI</td>
<td>18 (17.1)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>n</td>
</tr>
<tr>
<td>----------------------------</td>
<td>----</td>
</tr>
<tr>
<td>IVH (pure)</td>
<td>3</td>
</tr>
<tr>
<td>Ischemic stroke</td>
<td>5</td>
</tr>
<tr>
<td>Other vascular diseases</td>
<td>2</td>
</tr>
<tr>
<td>Brain tumor</td>
<td>22</td>
</tr>
<tr>
<td>Initial GCS</td>
<td>9</td>
</tr>
<tr>
<td>Initial mRS</td>
<td>4</td>
</tr>
<tr>
<td>ICU LOS (days)</td>
<td>19.5±13.9</td>
</tr>
</tbody>
</table>

Data are presented as n (%), median (interquartile range) or mean ± standard deviation.

BMI body mass index, DM diabetes mellitus, HTN hypertension, DI, dyslipidemia, SAH subarachnoid hemorrhage, ICH intracerebral hemorrhage, IVH intraventricular hemorrhage, TBI traumatic brain injury, GCS Glasgow coma scale, mRS modified Rankin scale, ICU intense care unit, LOS length of stay
**Fig. 1.** Protein requirements according to neurocritical treatment phases. During the active implementation of targeted temperature management and coma therapy in phase 1, the protein requirement was 1.49 ± 0.42 g/kg/day. However, in phase 2, as the intensive treatment was tapered, it increased to 2.18 ± 0.60 g/kg/day (p-value < 0.0001).

The unit of measurement is g/kg/day.
**Fig. 2.** Subgroup analyses of protein requirements based on specific diagnoses. In all subgroup analyses, the trends in phases 1 and 2 were consistent with those observed in the overall patient population. TBI traumatic brain injury, SAH subarachnoid hemorrhage, ICH intracerebral hemorrhage. The unit of measurement is g/kg/day, (p<0.001 ***, p<0.0001 ****).